© The Author 2006. Published by Oxford University Press.
ARTICLE |
A Model of Human Tumor Dormancy: An Angiogenic Switch From the Nonangiogenic Phenotype
Affiliations of authors: Departments of Surgery (GNN, EB, DZ, S-YK, DS, EF, RSW, LAA, JF, NA) and Biostatistics (DZ), Vascular Biology Program (GNN, EB, S-YK, DS, RSW, LAA, JF, NA), Children's Hospital, and Harvard Medical School, Boston, MA; The Gade Institute, Section for Pathology, University of Bergen, Bergen, Norway (OS, LAA)
Correspondence to: Judah Folkman, MD, Karp Family Research Laboratories 12.128, 300 Longwood Ave., Boston, MA 02115 (e-mail: judah.folkman{at}childrens.harvard.edu).
Background: Microscopic human cancers can remain dormant for life. Tumor progression depends on sequential events, including a switch to the angiogenic phenotype, i.e., initial recruitment of new vessels. We previously demonstrated that human tumors contain tumor cell populations that are heterogeneous in angiogenic activity. Here, we separated angiogenic from nonangiogenic human tumor cell populations and compared their growth. Methods: Severe combined immunodeficient (SCID) mice were inoculated with nonangiogenic human MDA-MB-436 breast adenocarcinoma, KHOS-24OS osteosarcoma, or T98G glioblastoma cells. Most of the resulting tumors remained microscopic (<1 mm diameter), but some eventually became angiogenic and enlarged and were used to isolate angiogenic tumor cells. Angiogenic and nonangiogenic tumor cells were inoculated into SCID mice, and time to the development of palpable tumors was determined. Cell proliferation was assayed in vitro by growth curves and in vivo by staining for proliferating cell nuclear antigen or Ki67. Microscopic tumors from both tumor cell populations were examined for histologic evidence of vascular development 14 days after inoculation in mice. Expression of the angiogenesis inhibitor thrombospondin-1 was examined by immunoblotting. Results: Nonangiogenic tumors of each tumor type developed palpable tumors after means of 119 days (range: 53–185 days) for breast cancer, 238 days (184–291 days) for osteosarcoma, and 226 days (150–301 days) for glioblastoma. Angiogenic cells developed palpable tumors within 20 days after inoculation. However, nonangiogenic and angiogenic cells of each tumor type had similar proliferation rates. Fourteen days after tumor cell inoculation, tumors from angiogenic cells showed evidence of functional vasculature. In contrast, nonangiogenic tumors remained microscopic in size with absent or nonfunctional vasculature. Thrombospondin-1 expression was statistically significantly lower (by five- to 23-fold, depending on tumor type) in angiogenic than nonangiogenic cells. Conclusions: This model provides a conceptual framework and a reproducible in vivo system to study unresolved central questions in cancer biology regarding the initiation, reversibility, and molecular regulation of the timing of the angiogenic switch.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: A Model of Human Tumor Dormancy: An Angiogenic Escape From the Nonangiogenic Phenotype
- Peyman Sardari Nia, Eric Van Marck, and Paul Van Schil
J Natl Cancer Inst 2007 99: 331.[Extract] [Full Text] [PDF]
Editorial about this Article
- Tumor Cell Populations Differ in Angiogenic Activity: A Model System for Spontaneous Angiogenic Switch Can Tell Us Why
- Masashi Narazaki and Giovanna Tosato
J Natl Cancer Inst 2006 98: 294-295.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  W. Yang, D. Luo, S. Wang, R. Wang, R. Chen, Y. Liu, T. Zhu, X. Ma, R. Liu, G. Xu, et al. TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis Clin. Cancer Res., September 1, 2008; 14(17): 5494 - 5502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Alix-Panabieres, S. Riethdorf, and K. Pantel Circulating Tumor Cells and Bone Marrow Micrometastasis Clin. Cancer Res., August 15, 2008; 14(16): 5013 - 5021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Barkan, H. Kleinman, J. L. Simmons, H. Asmussen, A. K. Kamaraju, M. J. Hoenorhoff, Z.-y. Liu, S. V. Costes, E. H. Cho, S. Lockett, et al. Inhibition of Metastatic Outgrowth from Single Dormant Tumor Cells by Targeting the Cytoskeleton Cancer Res., August 1, 2008; 68(15): 6241 - 6250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Demicheli, M. W. Retsky, W. J. M. Hrushesky, M. Baum, and I. D. Gukas The effects of surgery on tumor growth: a century of investigations Ann. Onc., June 10, 2008; (2008) mdn386v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Becker, N. Rohwer, T. Funakoshi, T. Cramer, W. Bernhardt, A. Birsner, J. Folkman, and R. J. D'Amato 2-Methoxyestradiol Inhibits Hypoxia-Inducible Factor-1{alpha} and Suppresses Growth of Lesions in a Mouse Model of Endometriosis Am. J. Pathol., February 1, 2008; 172(2): 534 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cervi, T.-T. Yip, N. Bhattacharya, V. N. Podust, J. Peterson, A. Abou-Slaybi, G. N. Naumov, E. Bender, N. Almog, J. E. Italiano Jr, et al. Platelet-associated PF-4 as a biomarker of early tumor growth Blood, February 1, 2008; 111(3): 1201 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ma and D. J. Waxman Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment Mol. Cancer Ther., November 1, 2007; 6(11): 2879 - 2890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kaneko, Z. Zhang, M. G. Mantellini, E. Karl, B. Zeitlin, M. Verhaegen, M. S. Soengas, M. Lingen, R. M. Strieter, G. Nunez, et al. Bcl-2 Orchestrates a Cross-talk between Endothelial and Tumor Cells that Promotes Tumor Growth Cancer Res., October 15, 2007; 67(20): 9685 - 9693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Overmoyer, P. Fu, C. Hoppel, T. Radivoyevitch, R. Shenk, M. Persons, P. Silverman, K. Robertson, N. P. Ziats, J. K. Wasman, et al. Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin Clin. Cancer Res., October 1, 2007; 13(19): 5862 - 5868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kamiyoshihara, T. Ibe, A. Takise, H. Itou, and I. Takeyoshi Pleural Metastases From Renal Cell Carcinoma 16 Years After Resection J. Clin. Oncol., September 1, 2007; 25(25): 4009 - 4011. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Abdollahi, C. Schwager, J. Kleeff, I. Esposito, S. Domhan, P. Peschke, K. Hauser, P. Hahnfeldt, L. Hlatky, J. Debus, et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer PNAS, July 31, 2007; 104(31): 12890 - 12895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Korsisaari, I. M. Kasman, W. F. Forrest, N. Pal, W. Bai, G. Fuh, F. V. Peale, R. Smits, and N. Ferrara From the Cover: Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice PNAS, June 19, 2007; 104(25): 10625 - 10630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Senan and E. F. Smit Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy Oncologist, April 1, 2007; 12(4): 465 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sardari Nia, E. Van Marck, and P. Van Schil Re: A Model of Human Tumor Dormancy: An Angiogenic Escape From the Nonangiogenic Phenotype J Natl Cancer Inst, February 21, 2007; 99(4): 331 - 331. [Full Text] [PDF]
|
|
|
|
|
|
R. N. Kaplan, S. Rafii, and D. Lyden Preparing the "Soil": The Premetastatic Niche Cancer Res., December 1, 2006; 66(23): 11089 - 11093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. O. Sakariassen, L. Prestegarden, J. Wang, K.-O. Skaftnesmo, R. Mahesparan, C. Molthoff, P. Sminia, E. Sundlisaeter, A. Misra, B. B. Tysnes, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells PNAS, October 31, 2006; 103(44): 16466 - 16471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Folkman Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin Sci. Signal., September 26, 2006; 2006(354): pe35 - pe35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Almog, V. Henke, L. Flores, L. Hlatky, A. L. Kung, R. D. Wright, R. Berger, L. Hutchinson, G. N. Naumov, E. Bender, et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis FASEB J, May 1, 2006; 20(7): 947 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Narazaki and G. Tosato Tumor cell populations differ in angiogenic activity: a model system for spontaneous angiogenic switch can tell us why. J Natl Cancer Inst, March 1, 2006; 98(5): 294 - 295. [Full Text] [PDF]
|
|